Comprehensive Stock Comparison
Compare Precision BioSciences, Inc. (DTIL) vs Alnylam Pharmaceuticals, Inc. (ALNY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ALNY | 65.2% revenue growth vs DTIL's 41.0% |
| Value | DTIL | Lower P/E (4.0x vs 49.0x) |
| Quality / Margins | ALNY | 8.4% net margin vs DTIL's -119.8% |
| Stability / Safety | DTIL | Beta 0.66 vs ALNY's 0.88, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ALNY | +34.9% vs DTIL's -22.1% |
| Efficiency (ROA) | ALNY | 6.3% ROA vs DTIL's -89.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Precision BioSciences is a clinical-stage biotechnology company developing gene editing therapies using its proprietary ARCUS platform. It generates revenue primarily through research collaborations and licensing deals with pharmaceutical partners — like its Servier partnership for CAR-T therapies — while advancing its own pipeline of in vivo gene editing and allogeneic CAR-T candidates. The company's key advantage is its ARCUS genome editing technology, which offers precise DNA cutting with potentially lower off-target effects than other gene editing approaches.
Alnylam Pharmaceuticals is a biopharmaceutical company that develops and commercializes RNA interference (RNAi) therapeutics for rare genetic diseases. It generates revenue primarily from sales of its approved RNAi drugs — ONPATTRO, GIVLAARI, OXLUMO, and others — targeting conditions like hereditary transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria. The company's key advantage is its pioneering RNAi technology platform and intellectual property estate, which creates a significant barrier to entry in the RNAi therapeutics space.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ALNY leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). DTIL leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
ALNY is the larger business by revenue, generating $3.7B annually — 5320.8x DTIL's $698,000. ALNY is the more profitable business, keeping 8.4% of every revenue dollar as net income compared to DTIL's -119.8%. On growth, ALNY holds the edge at +84.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| RevenueTrailing 12 months | $698,000 | $3.7B |
| EBITDAEarnings before interest/tax | -$87M | $557M |
| Net IncomeAfter-tax profit | -$84M | $314M |
| Free Cash FlowCash after capex | -$74M | $465M |
| Gross MarginGross profit ÷ Revenue | -96.3% | +81.8% |
| Operating MarginEBIT ÷ Revenue | -128.2% | +13.5% |
| Net MarginNet income ÷ Revenue | -119.8% | +8.4% |
| FCF MarginFCF ÷ Revenue | -105.6% | +12.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -97.7% | +84.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +18.1% | +3.1% |
Valuation Metrics
At 4.0x trailing earnings, DTIL trades at a 97% valuation discount to ALNY's 142.9x P/E.
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Market CapShares × price | $51M | $44.1B |
| Enterprise ValueMkt cap + debt − cash | -$5M | $45.4B |
| Trailing P/EPrice ÷ TTM EPS | 4.04x | 142.88x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 48.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 81.44x |
| Price / SalesMarket cap ÷ Revenue | 0.74x | 11.87x |
| Price / BookPrice ÷ Book value/share | 0.51x | 56.82x |
| Price / FCFMarket cap ÷ FCF | — | 94.70x |
Profitability & Efficiency
ALNY delivers a 39.8% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $-5 for DTIL. DTIL carries lower financial leverage with a 0.53x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 3.76x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs DTIL's 4/9, reflecting solid financial health.
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| ROE (TTM)Return on equity | -5.0% | +39.8% |
| ROA (TTM)Return on assets | -89.4% | +6.3% |
| ROICReturn on invested capital | — | +19.1% |
| ROCEReturn on capital employed | -22.6% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.53x | 3.76x |
| Net DebtTotal debt minus cash | -$56M | $1.3B |
| Cash & Equiv.Liquid assets | $86M | $1.7B |
| Total DebtShort + long-term debt | $30M | $3.0B |
| Interest CoverageEBIT ÷ Interest expense | -56.03x | 7.20x |
Total Returns (with DRIP)
A $10,000 investment in ALNY five years ago would be worth $22,381 today (with dividends reinvested), compared to $109 for DTIL. Over the past 12 months, ALNY leads with a +34.9% total return vs DTIL's -22.1%. The 3-year compound annual growth rate (CAGR) favors ALNY at 20.3% vs DTIL's -50.0% — a key indicator of consistent wealth creation.
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| YTD ReturnYear-to-date | +2.4% | -16.8% |
| 1-Year ReturnPast 12 months | -22.1% | +34.9% |
| 3-Year ReturnCumulative with dividends | -87.5% | +73.9% |
| 5-Year ReturnCumulative with dividends | -98.9% | +123.8% |
| 10-Year ReturnCumulative with dividends | -99.2% | +468.4% |
| CAGR (3Y)Annualised 3-year return | -50.0% | +20.3% |
Risk & Volatility
DTIL is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than ALNY's 0.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALNY currently trades 67.2% from its 52-week high vs DTIL's 47.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 0.88x |
| 52-Week HighHighest price in past year | $8.82 | $495.55 |
| 52-Week LowLowest price in past year | $3.53 | $205.87 |
| % of 52W HighCurrent price vs 52-week peak | +47.6% | +67.2% |
| RSI (14)Momentum oscillator 0–100 | 49.8 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 197K | 1.2M |
Analyst Outlook
| Metric | DTILPrecision BioScie… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $461.06 |
| # AnalystsCovering analysts | — | 51 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | 100 | 1.66 | -98.3% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 288.21 | +188.2% |
Alnylam Pharmaceuti… (ALNY) returned +124% over 5 years vs Precision BioScienc… (DTIL)'s -99%. A $10,000 investment in ALNY 5 years ago would be worth $22,381 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | $7M | $69M | +879.3% |
| Alnylam Pharmaceuti… (ALNY) | $47M | $3.7B | +7775.4% |
Alnylam Pharmaceuticals, Inc.'s revenue grew from $47M (2016) to $3.7B (2025) — a 62.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | -117.6% | 10.4% | +108.9% |
| Alnylam Pharmaceuti… (ALNY) | -8.7% | 8.4% | +197.1% |
Alnylam Pharmaceuticals, Inc.'s net margin went from -9% (2016) to 8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Precision BioScienc… (DTIL) | -0.49 | 1.04 | +312.2% |
| Alnylam Pharmaceuti… (ALNY) | -4.79 | 2.33 | +148.6% |
Alnylam Pharmaceuticals, Inc.'s EPS grew from $-4.79 (2016) to $2.33 (2025).
Chart 5Free Cash Flow — 5 Years
Precision BioSciences, Inc. generated $-59M FCF in 2024 (-252% vs 2021). Alnylam Pharmaceuticals, Inc. generated $465M FCF in 2025 (+165% vs 2021).
DTIL vs ALNY: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DTIL or ALNY a better buy right now?
Precision BioSciences, Inc. (DTIL) offers the better valuation at 4.0x trailing P/E, making it the more compelling value choice. Analysts rate Alnylam Pharmaceuticals, Inc. (ALNY) a "Buy" — based on 51 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DTIL or ALNY?
On trailing P/E, Precision BioSciences, Inc. (DTIL) is the cheapest at 4.0x versus Alnylam Pharmaceuticals, Inc. at 142.9x.
03Which is the better long-term investment — DTIL or ALNY?
Over the past 5 years, Alnylam Pharmaceuticals, Inc. (ALNY) delivered a total return of +123.8%, compared to -98.9% for Precision BioSciences, Inc. (DTIL). A $10,000 investment in ALNY five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ALNY returned +468.4% versus DTIL's -99.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DTIL or ALNY?
By beta (market sensitivity over 5 years), Precision BioSciences, Inc. (DTIL) is the lower-risk stock at 0.66β versus Alnylam Pharmaceuticals, Inc.'s 0.88β — meaning ALNY is approximately 32% more volatile than DTIL relative to the S&P 500. On balance sheet safety, Precision BioSciences, Inc. (DTIL) carries a lower debt/equity ratio of 53% versus 4% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — DTIL or ALNY?
Precision BioSciences, Inc. (DTIL) is the more profitable company, earning 10.4% net margin versus 8.4% for Alnylam Pharmaceuticals, Inc. — meaning it keeps 10.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13.5% versus -38.1% for DTIL. At the gross margin level — before operating expenses — DTIL leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DTIL or ALNY?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DTIL or ALNY better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.88), +468.4% 10Y return). Both have compounded well over 10 years (ALNY: +468.4%, DTIL: -99.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DTIL and ALNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: DTIL is a small-cap deep-value stock; ALNY is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.